MedPath

CRITICAL THERAPEUTICS

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:2

Trial Phases

3 Phases

Phase 1:1
Phase 2:3
Phase 4:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (60.0%)
Phase 1
1 (20.0%)
Phase 4
1 (20.0%)

Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: placebo
First Posted Date
2007-09-26
Last Posted Date
2008-03-21
Lead Sponsor
Critical Therapeutics
Target Recruit Count
36
Registration Number
NCT00534625

Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS

Phase 4
Terminated
Conditions
Asthma
Interventions
Drug: Placebo
First Posted Date
2007-06-14
Last Posted Date
2008-04-03
Lead Sponsor
Critical Therapeutics
Target Recruit Count
400
Registration Number
NCT00486343
Locations
🇺🇸

Critical Therapeutics, Lexington, Massachusetts, United States

Safety Study of Zileuton Injection in Patients With Asthma

Phase 1
Completed
Conditions
Asthma
First Posted Date
2006-03-06
Last Posted Date
2007-09-26
Lead Sponsor
Critical Therapeutics
Target Recruit Count
60
Registration Number
NCT00299065
Locations
🇺🇸

Allergy & Asthma Specialist Medical Group, Huntington Beach, California, United States

🇺🇸

Allergy and Asthma Medical Group and Research Center, San Diego, California, United States

🇺🇸

Colorado Allergy and Asthma Centers, PC, Englewood, Colorado, United States

and more 7 locations

CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)

Phase 2
Terminated
Conditions
Heart Valve Diseases
Coronary Disease
First Posted Date
2005-04-07
Last Posted Date
2006-03-17
Lead Sponsor
Critical Therapeutics
Target Recruit Count
150
Registration Number
NCT00107666
Locations
🇺🇸

Saddleback Memorial Medical Center, Laguna Hills, California, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

🇺🇸

Kaiser Permanente, San Francisco, California, United States

and more 14 locations

Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris

Phase 2
Conditions
Acne Vulgaris
First Posted Date
2004-12-08
Last Posted Date
2007-02-07
Lead Sponsor
Critical Therapeutics
Target Recruit Count
90
Registration Number
NCT00098358
Locations
🇺🇸

Therapeutics Clinical Research, San Diego, California, United States

🇺🇸

MedaPhase, Inc., Newnan, Georgia, United States

🇺🇸

Dermatology Specialists, PSC, Louisville, Kentucky, United States

and more 9 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.